These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

558 related articles for article (PubMed ID: 26070331)

  • 21. Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma.
    Mateos MV; Granell M; Oriol A; Martinez-Lopez J; Blade J; Hernandez MT; Martín J; Gironella M; Lynch M; Bleickardt E; Paliwal P; Singhal A; San-Miguel J
    Br J Haematol; 2016 Nov; 175(3):448-456. PubMed ID: 27434748
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A review discussing elotuzumab and its use in the second-line plus treatment of multiple myeloma.
    Offidani M; Corvatta L
    Future Oncol; 2018 Feb; 14(4):319-329. PubMed ID: 29091475
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Elotuzumab: A Review in Relapsed and/or Refractory Multiple Myeloma.
    Lamb YN
    Drugs; 2018 Sep; 78(14):1481-1488. PubMed ID: 30232695
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and TNF-α pathways.
    Balasa B; Yun R; Belmar NA; Fox M; Chao DT; Robbins MD; Starling GC; Rice AG
    Cancer Immunol Immunother; 2015 Jan; 64(1):61-73. PubMed ID: 25287778
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elotuzumab in the treatment of relapsed and refractory multiple myeloma.
    Grosicki S; Bednarczyk M; Barchnicka A; Grosicka O
    Future Oncol; 2021 May; 17(13):1581-1591. PubMed ID: 33478270
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study.
    Iida S; Nagai H; Kinoshita G; Miyoshi M; Robbins M; Pandya D; Bleickardt E; Chou T
    Int J Hematol; 2017 Mar; 105(3):326-334. PubMed ID: 27848182
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.
    Afifi S; Michael A; Lesokhin A
    Ann Pharmacother; 2016 Jul; 50(7):555-68. PubMed ID: 27083916
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SLAMF7 as a Promising Immunotherapeutic Target in Multiple Myeloma Treatments.
    Chu E; Wu J; Kang SS; Kang Y
    Curr Oncol; 2023 Aug; 30(9):7891-7903. PubMed ID: 37754488
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Clinical Pharmacology of Elotuzumab.
    Passey C; Sheng J; Mora J; Tendolkar A; Robbins M; Dodge R; Roy A; Bello A; Gupta M
    Clin Pharmacokinet; 2018 Mar; 57(3):297-313. PubMed ID: 28779463
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-CD38 and anti-SLAMF7: the future of myeloma immunotherapy.
    Zamagni E; Tacchetti P; Pantani L; Cavo M
    Expert Rev Hematol; 2018 May; 11(5):423-435. PubMed ID: 29582696
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns.
    Danhof S; Rasche L; Mottok A; Steinmüller T; Zhou X; Schreder M; Kilian T; Strifler S; Rosenwald A; Hudecek M; Einsele H; Gerhard-Hartmann E
    Ann Hematol; 2021 Jun; 100(6):1537-1546. PubMed ID: 33575947
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7.
    Kikuchi J; Hori M; Iha H; Toyama-Sorimachi N; Hagiwara S; Kuroda Y; Koyama D; Izumi T; Yasui H; Suzuki A; Furukawa Y
    Leukemia; 2020 Jan; 34(1):180-195. PubMed ID: 31358854
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CS1-directed monoclonal antibody therapy for multiple myeloma.
    Benson DM; Byrd JC
    J Clin Oncol; 2012 Jun; 30(16):2013-5. PubMed ID: 22547601
    [No Abstract]   [Full Text] [Related]  

  • 34. An Integrated Assessment of the Effects of Immunogenicity on the Pharmacokinetics, Safety, and Efficacy of Elotuzumab.
    Passey C; Mora J; Dodge R; Gibiansky L; Sheng J; Roy A; Bello A; Gupta M
    AAPS J; 2017 Mar; 19(2):557-567. PubMed ID: 28070715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma.
    van Rhee F; Szmania SM; Dillon M; van Abbema AM; Li X; Stone MK; Garg TK; Shi J; Moreno-Bost AM; Yun R; Balasa B; Ganguly B; Chao D; Rice AG; Zhan F; Shaughnessy JD; Barlogie B; Yaccoby S; Afar DE
    Mol Cancer Ther; 2009 Sep; 8(9):2616-24. PubMed ID: 19723891
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Elotuzumab, a potential therapeutic humanized anti-SLAMF7 monoclonal antibody, enhances natural killer cell-mediated killing of primary effusion lymphoma cells.
    Panaampon J; Kariya R; Okada S
    Cancer Immunol Immunother; 2022 Oct; 71(10):2497-2509. PubMed ID: 35262781
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab.
    Einsele H; Schreder M
    Ther Adv Hematol; 2016 Oct; 7(5):288-301. PubMed ID: 27695618
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma.
    van de Donk NW; Moreau P; Plesner T; Palumbo A; Gay F; Laubach JP; Malavasi F; Avet-Loiseau H; Mateos MV; Sonneveld P; Lokhorst HM; Richardson PG
    Blood; 2016 Feb; 127(6):681-95. PubMed ID: 26631114
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic antibodies for multiple myeloma.
    Ishida T
    Jpn J Clin Oncol; 2018 Nov; 48(11):957-963. PubMed ID: 30329116
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elotuzumab in Combination with Lenalidomide and Dexamethasone for Treatment-resistant Immunoglobulin Light Chain Amyloidosis With Multiple Myeloma.
    Iqbal SM; Stecklein K; Sarow J; Krabak M; Hillengass J; McCarthy P
    Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):e33-e36. PubMed ID: 30337238
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.